Simplified formulations that allow for dosing flexibility and require less time to develop are often used instead of the to-be-marketed formulation. Dosage forms such as oral solutions, powders (including powders for oral suspensions), and capsules are preferred owing to their dosing flexibility. To develop a formulation suitable for human ADME studies, we evaluated the effectiveness of known solubility enhancement approaches, namely developing oral solutions and amorphous solid dispersions of S-892216.